system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adenocarcinoma, Clear Cell, Adenocarcinoma, Mucinous, Biomarkers, Tumor, Blotting, Western, Carcinoma, Endometrioid, Eye Proteins, Female, Gene Expression Regulation, Neoplastic, Humans, Microcirculation, Neoplasms, Neovascularization, Pathologic, Nerve Growth Factors, Ovarian Neoplasms, Reverse Transcriptase Polymerase Chain Reaction, Serpins, Vascular Endothelial Growth Factor A.
user
Is the reduction in pigment epithelium-derived factor a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor? Context: Angiogenesis is a critical factor in the progression of solid tumors and metastasis. The aim of this study was to characterise the roles of angiogenic and anti-angiogenic factors on ovarian cancer. The expression levels of vascular endothelial growth factor (VEGF, angiogenic factor) and pigment epithelial growth factor (PEDF, anti-angiogenic factor) were measured by real-time polymerase chain reaction and Western blotting in ovarian tumors. Microvessel density (MVD) was evaluated by the total microvessel length in high-power field of tumor tissue preparations. MVD correlated with tumor malignancy. The tissues with the highest expression levels of VEGF (VEGF-H) were malignant tumors. The VEGF expression levels in some malignant tumors (VEGF-L) were as low as that in benign tumors. Therefore, the expression of PEDF was examined. The PEDF expression levels in VEGF-L malignant tumors were significantly lower than those in benign tumors. On the other hand, the PEDF expression levels in VEGF-H malignant tumor tissues were not significantly different from those in benign tumors.
assistant
The reduction in PEDF expression levels may be, in part, responsible for tumor malignancy in VEGF-L ovarian tumors. Furthermore, PEDF may be a useful marker of malignancy in VEGF-L ovarian tumors. Final Decision: yes